$PLRX

Pliant Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Medicinal and Botanical Manufacturing

PRICE

$5.27 ▲6.694%

Last Close

VOLUME

210,985

DAY RANGE

4.825 - 5.34

52 WEEK

3.97 - 33.95

Join Discuss about PLRX with like-minded investors

profile
@dros #droscrew
recently

Upgrades 11/24: $AEG $CVX $DEO $DLTR $FMX $GRUB $SYBX $YSG .. Downgrades 11/24: $BABA $BBY $GPS $HTA $JACK $JWN $NOAH $PLAN $RPM $TITN +Initiations 11/24: $AURA $AVY $BFRI $BTTX $CFG $DSEY $GPK $LIAN $MYNA $OCUP $PLRX $SLGN $SPAQ $SPOT $TRDA .. -Initiations 11/24:

40 Replies 11 👍 10 🔥

Key Metrics

Market Cap

190.25 M

Beta

1.25

Avg. Volume

248.56 K

Shares Outstanding

36.17 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-08

Next Dividend Date

Company Information

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.

CEO: Bernard Coulie

Website:

HQ: 260 Littlefield Avenue South San Francisco, 94080 California

Related News